scorecardresearchAjanta Pharmaceuticals Share Price Live NSE, BSE, Today - Ajanta Pharmaceuticals

Ajanta Pharmaceuticals

BSE: 532331 | NSE: AJANTPHARM | ISIN: INE031B01049 | SECTOR: Biotechnology & Drugs

2,412.80 18.90 (0.79%)

30 May 2024, 10:26 (IST)
  • Open

  • High

  • Low

  • Prev Close

  • P/E

  • Median P/E

  • P/B

  • Median P/B

  • Market Cap

  • Volume

  • Vol. (20 day Avg.)

  • PEG

  • Div.Yield

  • Bid

  • Ask


Promoter Pledge Holding - 8.12%

Promoter NameNo of SharesPercentage
Ravi P Agrawal, trustee Ravi Agrawal Trust53,82,6424.27%
Aayush M Agrawal, trustee Aayush Agrawal Trust48,38,2023.84%

Company Description

  • Biotechnology & Drugs
  • BSE

  • NSE

  • ISIN


Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.

Company Officers

  • Madhusudan Agrawal

    Executive Vice Chairman of the Board
  • Arvind Agrawal

    Chief Financial Officer
  • Gaurang Shah

    Vice President - Legal, Company Secretary
  • Rajesh Agrawal

    Joint Managing Director, Executive Director
  • Yogesh Agrawal

    Managing Director, Executive Director